Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - pegfilgrastim - nevtropenija - immunostimulants, - skrajšanje trajanja nevtropenija in pojavnost vročinskih nevtropenija pri bolnikih, zdravljenih s citotoksično kemoterapijo za malignosti (razen kronično mieloično levkemijo in mielodisplastični sindrom).

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - alendronska kislina - tableta - alendronska kislina 70 mg / 1 tableta - alendronska kislina

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

accord healthcare - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - trastuzumab - breast neoplasms; stomach neoplasms - antineoplastična sredstva - breast cancermetastatic breast cancer zercepac is indicated for the treatment of adult patients with her2 positive metastatic breast cancer (mbc):as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease. pred kemoterapijo, morajo imeti vključen vsaj anthracycline in taxane, razen če je bolnikov, ki so neprimerni za te oblike zdravljenja. hormonski receptor pozitivni bolniki morajo tudi ni uspelo hormonske terapije, razen če je bolnikov, ki so neprimerni za te oblike zdravljenja.                      in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable. v kombinaciji z docetaxel za zdravljenje teh bolnikov, ki še niso prejeli kemoterapijo za njihovo metastatskim bolezni. v kombinaciji z zaviralec aromataze za zdravljenje postmenopausal bolnikih z hormon-receptor pozitivno mbc, ki še niso bila obdelana z trastuzumab. early breast cancer zercepac is indicated for the treatment of adult patients with her2 positive early breast cancer (ebc). naslednje operacijo, kemoterapijo (neoadjuvant ali adjuvant) in radioterapija (če je primerno). naslednje adjuvant kemoterapijo z doxorubicin in ciklofosfamid, v kombinaciji z paclitaxel ali docetaxel. v kombinaciji z adjuvant kemoterapijo, sestavljen iz docetaxel in carboplatin. in combination with neoadjuvant chemotherapy followed by adjuvant zercepac therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter. zercepac should only be used in patients with metastatic or early breast cancer whose tumours have either her2 overexpression or her2 gene amplification as determined by an accurate and validated assay. metastatic gastric cancer zercepac in combination with capecitabine or 5-fluorouracil and cisplatin is indicated for the treatment of adult patients with her2 positive metastatic adenocarcinoma of the stomach or gastro-oesophageal junction who have not received prior anti-cancer treatment for their metastatic disease. zercepac should only be used in patients with metastatic gastric cancer (mgc) whose tumours have her2 overexpression as defined by ihc2+ and a confirmatory sish or fish result, or by an ihc 3+ result. točne in veljavne testa metode je treba uporabiti.

Evropska unija - slovenščina - EMA (European Medicines Agency)

accord healthcare s.l.u. - doxorubicin hydrochloride, liposomal - ovarian neoplasms; sarcoma, kaposi; multiple myeloma - doxorubicin - zolsketil pegylated liposomal is a medicine used to treat the following types of cancer in adults:• breast cancer that has spread to other parts of the body in patients at risk of heart problems. zolsketil pegylated liposomal is used on its own for this disease;• advanced ovarian cancer in women whose previous treatment including a platinum-based cancer medicine has stopped working;• multiple myeloma (a cancer of the white blood cells in the bone marrow), in patients with progressive disease who have received at least one other treatment in the past and have already had, or are unsuitable for, a bone marrow transplantation. zolsketil pegylated liposomal is used in combination with bortezomib (another cancer medicine);• kaposi’s sarcoma in patients with aids who have a very damaged immune system. kaposi’s sarcoma is a cancer that causes abnormal tissue to grow under the skin, on moist body surfaces or on internal organs. zolsketil pegylated liposomal contains the active substance doxorubicin and is a ‘hybrid medicine’. this means that it is similar to a ‘reference medicine’ containing the same active substance called adriamycin. however, in zolsketil pegylated liposomal the active substance is enclosed in tiny fatty spheres called liposomes, whereas this is not the case for adriamycin.

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

mylan healthcare d.o.o. - sotalol - tableta - sotalol 70,54 mg / 1 tableta - sotalol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ge healthcare as - jod - raztopina za injiciranje - jod 270 mg / 1 ml - jodiksanol

Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

ge healthcare as - jod - raztopina za injiciranje - jod 270 mg / 1 ml - jodiksanol